362703-35-3

Usage

Uses

Used in Pharmaceutical Synthesis:
METHYL 4-AMINOMETHYL-1-BOC-PIPERIDINE-4-CARBOXYLATE is used as a building block in organic synthesis and medicinal chemistry for its ability to contribute to the creation of various pharmaceuticals and fine chemicals. Its Boc-protected nature ensures that the compound can be used in multi-step synthesis processes without premature reactivity of the amine group.
Used in Organic Synthesis:
In the field of organic synthesis, METHYL 4-AMINOMETHYL-1-BOC-PIPERIDINE-4-CARBOXYLATE is used as a precursor for the synthesis of complex organic molecules, taking advantage of its reactivity and the presence of the piperidine ring, which can be further modified to achieve desired chemical properties and biological activities.
Used in Medicinal Chemistry:
METHYL 4-AMINOMETHYL-1-BOC-PIPERIDINE-4-CARBOXYLATE is utilized as a key intermediate in the development of new drugs, where its functional groups can be tailored to interact with specific biological targets, potentially leading to the discovery of novel therapeutic agents.

InChI:InChI=1/C13H24N2O4/c1-12(2,3)19-11(17)15-7-5-13(9-14,6-8-15)10(16)18-4/h5-9,14H2,1-4H3

Upstream product

• 1016258-66-4 1-(tert-butyl) 4-ethyl 4-cyanopiperidine-1,4-dicarboxylate 
• 4395-98-6 4-cyanopiperidine 
• 159635-50-4 Bis-(2-bromo-ethyl)-carbamic acid tert-butyl ester 
• 362703-34-2 1-tert-butyl 4-methyl 4-cyanopiperidine-1,4-dicarboxylate 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 362703-36-4 4-{[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-methyl}-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester 
• 1338251-86-7 C₂₅H₃₂N₂O₆ 
• 1338251-87-8 C₂₅H₃₂N₂O₆ 
• 1338251-88-9 C₂₅H₃₂N₂O₆ 
• 1338251-89-0 C₂₅H₂₉F₃N₂O₅ 
• 1338251-90-3 C₂₅H₂₉F₃N₂O₅ 
• 1338251-91-4 C₂₅H₂₉F₃N₂O₅ 
• 1338251-92-5 C₂₉H₃₆N₂O₆ 
• 1338251-93-6 C₂₅H₃₂N₂O₅ 
• 1338251-94-7 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-95-8 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-96-9 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-97-0 C₂₃H₂₃Cl₂F₃N₂O₃ 
• 1338251-98-1 C₂₃H₂₃Cl₂F₃N₂O₃ 

Relevant academic research and scientific papers

LIM KINASE INHIBITORS

The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In particular, the present invention relates to new LIMK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said Compounds in the manufacture of a medicament for the application to a number of therapeutic indications including Ophthalmic and intestinal diseases.

Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers

To obtain selective and potent inhibitor for T-type calcium channel by ligand based drug design, 4-piperidinecarboxylate and 4-piperidinecyanide derivatives were prepared and evaluated for in vitro and in vivo activity against α1G calcium channel. Among them, several compounds showed good T-type calcium channel inhibitory activity and minimal off-target activity over hERG channel (% inhibition at 10 μM = 61.85-71.99, hERG channel IC50 = 1.57 ± 0.14-4.98 ± 0.36 μM). Selected compound 31a was evaluated on SNL model of neuropathic pain and showed inhibitory effect on mechanical allodynia.

Synthesis and structure-activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

A novel series of achiral TNF-α converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-α production in an LPS-stimulated whole blood assay with an IC5

Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha

The present application describes novel β-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3